MARKET

AUPH

AUPH

Aurinia Pharma
NASDAQ

Real-time Quotes | Nasdaq Last Sale

14.92
+0.06
+0.40%
After Hours: 15.19 +0.27 +1.81% 19:37 12/04 EST
OPEN
14.89
PREV CLOSE
14.86
HIGH
15.22
LOW
14.83
VOLUME
892.22K
TURNOVER
--
52 WEEK HIGH
21.93
52 WEEK LOW
7.95
MARKET CAP
1.88B
P/E (TTM)
-10.1600
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Aurinia Pharmaceuticals to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced its participation in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations will be available for registered attendees via the Piper Sandler conference site through December 3.
Business Wire · 2d ago
Aurinia Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSX:AUP) ("Aurinia" or the "Company"), a late-stage clinical biopharmaceutical company, today announced that the Company's Compensation Committee granted the newly appointed Executive Vice President, General Counsel, Corporate Secretary & Chief Compliance Officer, Stephen Robertson, a non-qualified stock option to purchase an aggregate of 298,924 common shares on November 16, 2020. The option has a per share exercise price of $13.40 USD, the closing trading price on November 13, 2020. One-third of the shares underlying the option vest in November 2021, and the balance of the shares vest in a series of 24 equal monthly installments thereafter. The inducement option was granted as an inducement material to the new employee entering into employment with Aurinia in accordance with Nasdaq Listing Rule 5635(c)(4). For the purposes of TSX approval, the Company relied on the exemption set forth in Section 602.1 of the TSX Company Manual, which provides that the TSX will not apply its standards to certain transactions involving eligible inter-listed issuers on a recognized exchange, such as Nasdaq.
BusinessWire · 11/20 19:00
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET.
Business Wire · 11/12 21:05
Aurinia Pharmaceuticals to Present at the 2020 Jefferies Virtual London Healthcare Conference
Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH / TSX: AUP) (the "Company") today announced that members of the senior management team will participate in a fireside chat during the 2020 Jefferies Virtual London Healthcare Conference on November 19, 2020 at 11:25 a.m. ET.
BusinessWire · 11/12 18:05
Aurinia Pharmaceuticals: Q3 Earnings Insights
Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) fell 0.15% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share decreased 33.33% year over year to ($0.28), which missed the estimate of ($0.15).Revenue of $29,000 decreased by 87.39% year over year, which missed the estimate of $50,000.Guidance Earnings guidance hasn't been issued by the company for now.Aurinia Pharmaceuticals hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 10, 2020View more earnings on AUPHTime: 04:30 PMET Webcast URL: https://78449.themediaframe.com/dataconf/productusers/auph/mediaframe/41949/indexl.htmlTechnicals 52-week high: $21.93Company's 52-week low was at $4.90Price action over last quarter: down 4.80%Company Description Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing voclosporin, an investigational drug, for the treatment of lupus nephritis (LN), focal segmental glomerulosclerosis (FSGS), and Dry Eye Syndrome (DES). Geographically, it derives maximum revenue from the United States followed by China.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 10, 2020 * 12 Healthcare Stocks Moving In Tuesday's Intraday Session(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 11/10 21:30
Aurinia Reports Third Quarter 2020 Financial Results and Recent Operational Highlights
--- Cash, cash equivalents and investments totaled approximately $421 million at September 30, 2020 -
BusinessWire · 11/10 18:02
Aurinia Presents Integrated Time to Renal Response Data from the AURA-LV and AURORA Trials, along with Voclosporin Drug-Drug Interaction Data at ACR Convergence 2020
--- DDI study demonstrates no clinically meaningful interaction between voclosporin and MMF, supporting differentiation as a potential best-in-class CNI -
BusinessWire · 11/09 18:05
Aurinia Tanks 10% As Dry Eye Trial Fails To Reach Primary Endpoint
Shares in Aurinia Pharmaceuticals (AUPH) tanked 10% after-hours after the biopharma announced disappointing topline data from the Phase 2/3 Audrey clinical study evaluating voclosporin ophthalmic solution (VOS) for the potential treatment of dry eye syndrome (DES).The trial did not achieve statistical significance on its primary endpoint of a 10mm or greater improvement in the Schirmer Tear Test (STT) at four weeks between active dose groups of VOS compared to vehicle.As a result, Aurinia is now suspending the development program for VOS.“While surprised by these results, we remain focused on preparing voclosporin for lupus nephritis – which has a different formulation and delivery mechanism compared to VOS. As we approach our lupus nephritis PDUFA action date, the Aurinia team remains committed to our mission of developing novel treatments for people with debilitating and severe autoimmune disease” commented CEO Peter Greenleaf.The trial was a randomized, double-masked, vehicle-controlled, dose-ranging study evaluating the efficacy and safety of VOS in subjects with DES. A total of 508 subjects were enrolled.As well as the primary endpoint, secondary outcome measures evaluated in the trial included STT at other time points, Fluorescein Corneal Staining (FCS) at multiple time points, change in eye dryness, burning/stinging, itching, photophobia, eye pain and foreign body sensation at multiple time points, and additional safety endpoints.According to Aurinia, initial analysis of these secondary outcomes suggests dose-dependent activity and safety were observed across dose groups compared to vehicle. Further analysis will be conducted over the coming weeks, the company says. (See AUPH stock analysis on TipRanks).On a year-to-date basis, the stock is now trading down 23% yet the Street has a bullish Strong Buy consensus on Aurinia. That’s with 4 recent buy ratings. The average analyst price target indicates upside potential of over 60% lies ahead.Oppenheimer’s Justin Kim remains enthusiastic about the company’s prospects in lupus nephritis (LN). He reiterated his buy rating on AUPH with a $20 price target on November 2. Kim cites Aurinia’s “thoughtful and committed approach to launching this potential therapeutic in the LN space, supported by the drug’s highly differentiated product profile.”Related News: J&J Strikes Covid-19 Vaccine Manufacturing Deal With Aspen Moderna Scores $1.1B From Covid-19 Vaccine Deposits; Shares Rise 3% Opko Health Tanks 10% Despite Solid Q3 Covid Testing Revenue More recent articles from Smarter Analyst: * AMC Sinks 8.5% On $47.7M Equity Offering; Street Sees 80% Upside * Nutrien Sinking 4% Despite Earnings Beat On Strong Potash Sales * Mondelez Beats Q3 Estimates On Elevated Demand In Developed Markets * Vornado Flips To Loss in 3Q; Street Sees 29% Upside
SmarterAnalyst · 11/03 06:55
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of AUPH. Analyze the recent business situations of Aurinia Pharma through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average AUPH stock price target is 23.20 with a high estimate of 30.00 and a low estimate of 20.00.
EPS
Institutional Holdings
Institutions: 186
Institutional Holdings: 69.16M
% Owned: 54.87%
Shares Outstanding: 126.04M
TypeInstitutionsShares
Increased
66
13.69M
New
48
-909.10K
Decreased
27
6.59M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.87%
Pharmaceuticals & Medical Research
+1.71%
Key Executives
Chairman/Independent Director
George Milne
President/Chief Executive Officer/Director
Peter Greenleaf
Chief Financial Officer
Dennis Bourgeault
Chief Operating Officer
Michael Martin
Executive Vice President/Chief Compliance Officer/General Counsel/Secretary
Stephen Robertson
Executive Vice President
Maxwell Donley
Executive Vice President
Robert Huizinga
Senior Vice President/IR Contact Officer
Glenn Schulman
Chief Marketing Officer
Neil Solomons
Vice President/Director of Sales
Fran Lynch
Vice President/Director of Marketing
Chris Hays
Vice President
Cara Felish
Vice President
Tim Hermes
Other
Max Colao
Director
Daniel Billen
Director
R. Hector MacKay-Dunn
Independent Director
Joseph Hagan
Independent Director
Michael Hayden
Independent Director
David Jayne
Independent Director
Jill Leversage
Independent Director
Timothy Walbert
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About AUPH
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Voclosporin is a calcineurin inhibitor (CNI). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Aurinia Pharmaceuticals Inc stock information, including NASDAQ:AUPH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUPH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading AUPH stock methods without spending real money on the virtual paper trading platform.